These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30664338)
1. Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine. Wu L; Gerdts EA; Alam A Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30664338 [No Abstract] [Full Text] [Related]
2. Discussing the Risk of Tardive Dyskinesia With Patients and Screening for Signs. Manning JS J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505187 [TBL] [Abstract][Full Text] [Related]
3. Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine. Garakani A Prim Care Companion CNS Disord; 2018 Dec; 20(6):. PubMed ID: 30550646 [No Abstract] [Full Text] [Related]
4. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080 [TBL] [Abstract][Full Text] [Related]
5. Switch to a manic episode after desvenlafaxine discontinuation in bipolar disorder. Muquebil Ali Al Shaban-Rodríguez OW; Álvarez de Morales E; Rodríguez-Turiel C; Fernández-Menéndez MA; García-Álvarez G Actas Esp Psiquiatr; 2018 Jul; 46(4):156-8. PubMed ID: 30079929 [No Abstract] [Full Text] [Related]
6. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis. Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270 [TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Laoutidis ZG; Kioulos KT Pharmacopsychiatry; 2015 Sep; 48(6):187-99. PubMed ID: 26205685 [TBL] [Abstract][Full Text] [Related]
8. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. Soares CN; Zhang M; Boucher M CNS Spectr; 2019 Jun; 24(3):322-332. PubMed ID: 29140227 [TBL] [Abstract][Full Text] [Related]
9. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. Khan A; Musgnung J; Ramey T; Messig M; Buckley G; Ninan PT J Clin Psychopharmacol; 2014 Jun; 34(3):365-8. PubMed ID: 24717247 [TBL] [Abstract][Full Text] [Related]
10. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354 [TBL] [Abstract][Full Text] [Related]
11. Desvenlafaxine withdrawal serotonergic syndrome in a newborn. Sánchez Malo MJ; Hidalgo Sanz J; Curto Simón B Med Clin (Barc); 2021 Jul; 157(2):93-94. PubMed ID: 32951880 [No Abstract] [Full Text] [Related]
12. Combined use of desvenlafaxine and electroconvulsive therapy. Martín-Larrégola M; Gómez-Arnau J; Rodríguez-Salgado B; Dolengevich-Segal H Actas Esp Psiquiatr; 2016; 44(2):79-82. PubMed ID: 27099215 [No Abstract] [Full Text] [Related]
13. Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor? Gurunathan U J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):e16-e18. PubMed ID: 29153932 [No Abstract] [Full Text] [Related]
14. False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. Farley TM; Anderson EN; Feller JN BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170178 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder. Findling RL; Groark J; Tourian KA; Ramaker SA; Chiles D; Yang L; Nichols AI J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):909-921. PubMed ID: 27428303 [TBL] [Abstract][Full Text] [Related]
16. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346 [TBL] [Abstract][Full Text] [Related]
17. A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder. Ng CH; Bousman C; Smith DJ; Dowling N; Byron K; King J; Sarris J Pharmacopsychiatry; 2016 Sep; 49(5):210-212. PubMed ID: 27023264 [TBL] [Abstract][Full Text] [Related]
18. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. Reddy S; Fayyad R; Edgar CJ; Guico-Pabia CJ; Wesnes K J Psychopharmacol; 2016 Jun; 30(6):559-67. PubMed ID: 27009044 [TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447 [TBL] [Abstract][Full Text] [Related]
20. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]